J&J Loses Trial Over Risperdal and Male Breast
The Wall Street Journal Pharmalot Blog 2015-02-24 In a setback to Johnson & Johnson, a Philadelphia jury decided the health care giant must pay $2.5 million in damages for failing to warn that its Risperdal antipsychotic could cause gynecomastia, which is abnormal development of breasts in males. The lawsuit was brought by the family of […]
